Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The REVIVED–BCIS2 trial: lessons and outcomes

Nature Cardiovascular Research volume 1, pages 963–964 (2022)Cite this article

Subjects

The REVIVED trial provides critical evidence on the management of patients with ischemic left ventricular dysfunction, highlighting the importance of optimal medical therapy. At the same time, it is another reminder of the fact that we are far from reaching adequate representation of women in cardiovascular disease trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Perera, D. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2206606 (2022).

    Article  PubMed  Google Scholar 

  2. Rahimtoola, S. H. Am Heart J 117, 211–221 (1989).

    Article  CAS  PubMed  Google Scholar 

  3. Velazquez, E. J. et al. N. Engl. J. Med. 364, 1607–1616 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Velazquez, E. J. et al. N. Engl. J. Med. 374, 1511–1520 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Maron, D. J. et al. N. Engl. J. Med. 382, 1395–1407 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Prasad, A. et al. J. Am. Coll. Cardiol. 54, 477–486 (2009).

    Article  PubMed  Google Scholar 

  7. Petrie, M. C. et al. Circulation 134, 1314–1324 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Vogel, B. et al. Lancet 397, 2385–2438 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    Roxana Mehran & Birgit Vogel

Authors
  1. Roxana Mehran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgit Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roxana Mehran.

Ethics declarations

Competing interests

R.M. reports institutional research payments from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Amgen, Applied Therapeutics, Arena, AstraZeneca, AtriCure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Humacyte, Idorsia, Janssen, Magenta, Medtronic, Novartis, OrbusNeich, PhaseBio, Philips, Pi-Cardia, RenalPro, RM Global, Shockwave, Vivasure and Zoll; personal fees from Cine-Med Research, Novartis and WebMD; and equity (<1%) in Applied Therapeutics, Elixir Medical, Stel and ControlRad (spouse). R.M. is also a member of the AMA scientific advisory board, the ACC board of trustees, and the SCAI Women in Innovations Committee; is an associate editor for Journal of the American Medical Association; and is Cardiovascular Research Foundation faculty (no fee). B.V. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehran, R., Vogel, B. The REVIVED–BCIS2 trial: lessons and outcomes. Nat Cardiovasc Res 1, 963–964 (2022). https://doi.org/10.1038/s44161-022-00156-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-022-00156-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing